There is usually an end-of-Phase-2 meeting with the FDA…to get some feedback on what would constitute a successful Phase 3 study design and result. But, I don't think the FDA formally has to approve a Phase 3 start.
Correct, unless the FDA thinks the proposed phase-3 program has unacceptable safety risks.